Fontolizumab
As of the edition of 20 October 2026, Fontolizumab is an antibody: stopped in 2006; acts on IFNG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2006
- Kind
- Antibody
- Registered trials
- 1, 1 stopped early
- Disease areas
- Bones, joints and muscles; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IFNG | Interferon gamma | P01579 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| PDL BioPharma | Lead sponsor of trials | 2005 to now |